Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
BMJ Case Rep ; 16(7)2023 Jul 19.
Artículo en Inglés | MEDLINE | ID: mdl-37474142

RESUMEN

Intravitreal methotrexate injection (400 µg/0.1 mL) is the current mainstay for managing vitreoretinal lymphoma. Various complications associated with intravitreal methotrexate are cataract, keratopathy, maculopathy, sterile endophthalmitis, optic atrophy, vitreous haemorrhage, etc. The most common adverse effect of intravitreal methotrexate is keratopathy occurring in more than half of cases. The severity may range from diffuse punctate keratopathy to severe epitheliopathy leading to photophobia, pain, visual blurring, epiphora, etc. This may become a reason for reduced compliance with treatment. The management of these complications includes oral folic acid, topical folinic acid supplementations and reduced frequency or cessation of methotrexate intravitreal injections. Here, we report a simple method of eyewash in a large amount of balanced salt solution after the intravitreal injection procedure to reduce the severity of keratopathy, which helped the patient tolerate the treatment.


Asunto(s)
Neoplasias del Sistema Nervioso Central , Enfermedades de la Córnea , Neoplasias del Ojo , Linfoma no Hodgkin , Neoplasias de la Retina , Humanos , Metotrexato/uso terapéutico , Inyecciones Intravítreas , Neoplasias de la Retina/tratamiento farmacológico , Cuerpo Vítreo , Neoplasias del Ojo/tratamiento farmacológico , Enfermedades de la Córnea/inducido químicamente , Cloruro de Sodio/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA